Endres; Gregory William

Patent Applications and Registrations

Patent applications and USPTO patent grants for Endres; Gregory William.The latest application filed is for "ready-to-extract platforms for chemical analysis and quantification of unknown samples using spiked matrix standards".

Company Profile

7.15.20

Endres; Gregory William - Saline MI

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions Grant 11,066,361 - Barrett , et al. July 20, 2	2021-07-20
Ready-to-extract Platforms For Chemical Analysis And Quantification Of Unknown Samples Using Spiked Matrix Standards App 20210003488 - ENDRES; Gregory William ; et al.	2021-01-07
Methods, systems, and compositions for promoting bone growth Grant 10,729,810 - Barrett , et al.	2020-08-04
Difluorolactam Compounds As Ep4 Receptor-selective Agonists For Use In The Treatment Of Ep4-mediated Diseases And Conditions App 20200207709 - Barrett; Stephen Douglas ; et al.	2020-07-02
Difluorolactam compounds as EP.sub.4 receptor-selective agonists for use in the treatment of EP.sub.4-mediated diseases and conditions Grant 10,556,862 - Barrett , et al. Feb	2020-02-11
Methods Of Synthesizing A Prostacyclin Analog App 20200002261 - Hering; Kirk William ; et al.	2020-01-02
Methods of synthesizing a prostacyclin analog Grant 10,450,257 - Hering , et al. Oc	2019-10-22
Difluorolactam Compounds As Ep4 Receptor-selective Agonists For Use In The Treatment Of Ep4-mediated Diseases And Conditions App 20190092722 - Barrett; Stephen Douglas ; et al.	2019-03-28
Amine salts of a prostacyclin analog Grant 10,155,716 - Chambournier , et al. Dec	2018-12-18
Methods Of Synthesizing A Prostacyclin Analog App 20180141889 - Hering; Kirk William ; et al.	2018-05-24
Amine Salts Of A Prostacyclin Analog App 20180118656 - Chambournier; Gilles ; et al.	2018-05-03
Methods of synthesizing a prostacyclin analog Grant 9,908,834 - Hering , et al. March 6, 2	2018-03-06
Amine salts of a prostacyclin analog Grant 9,890,104 - Chambournier , et al. February 13, 2	2018-02-13
Methods Of Synthesizing A Prostacyclin Analog App 20170297995 - Hering; Kirk William ; et al.	2017-10-19
Difluorolactam compositions for EP.sub.4-mediated osteo related diseases and conditions Grant 9,701,630 - Barrett , et al. July 11, 2	2017-07-11
Lactam compounds as EP.sub.4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions Grant 9,688,627 - Barrett , et al. June 27, 2	2017-06-27
Lactam compounds as EP.sub.4 receptor-selective agonists for use in the treatment of EP.sub.4-mediated diseases and conditions Grant 9,676,712 - Barrett , et al. June 13, 2	2017-06-13
Difluorolactam Compounds As Ep4 Receptor-selective Agonists For Use In The Treatment Of Ep4-mediated Diseases And Conditions App 20170066751 - Barrett; Stephen Douglas ; et al.	2017-03-09
Difluorolactam Compositions For Ep4-mediated Osteo Related Diseases And Conditions App 20160340306 - Barrett; Stephen Douglas ; et al.	2016-11-24
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions Grant 9,487,478 - Barrett , et al. November 8, 2	2016-11-08
Amine Salts of a Prostacyclin Analog App 20160289158 - CHAMBOURNIER; GILLES ; et al.	2016-10-06
Difluorolactam compositions for EP4-mediated osteo related diseases and conditions Grant 9,440,919 - Barrett , et al. September 13, 2	2016-09-13
Methods, Systems, And Compositions For Promoting Bone Growth App 20160158413 - Barrett; Stephen Douglas ; et al.	2016-06-09
Lactam Compounds As Ep4 Receptor-selective Agonists For Use In The Treatment Of Ep4-mediated Diseases And Conditions App 20160060216 - Barrett; Stephen Douglas ; et al.	2016-03-03
Lactam Compounds As Ep4 Receptor-selective Agonists For Use In The Treatment Of Ep4-mediated Diseases And Conditions App 20160031811 - Barrett; Stephen Douglas ; et al.	2016-02-04
Difluorolactam Compounds As Ep4 Receptor-selective Agonists For Use In The Treatment Of Ep4-mediated Diseases And Conditions App 20160024006 - Barrett; Stephen Douglas ; et al.	2016-01-28
Fluorescent Molecular Probes For Use In Assays That Measure Test Compound Competitive Binding With Sam-utilizing Proteins App 20150323542 - Barrett; Stephen Douglas ; et al.	2015-11-12
Fluorescent Molecular Probes For Use In Assays That Measure Test Compound Competitive Binding With Sam-utilizing Proteins App 20150322107 - Barrett; Stephen Douglas ; et al.	2015-11-12
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions Grant 9,180,116 - Barrett , et al. November 10, 2	2015-11-10
Methods of Synthesizing a Prostacyclin Analog App 20150315114 - HERING; Kirk Willam ; et al.	2015-11-05
Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins Grant 9,120,820 - Barrett , et al. September 1, 2	2015-09-01
Difluorolactam Compositions For Ep4-mediated Osteo Related Diseases And Conditions App 20150174099 - Barrett; Stephen Douglas ; et al.	2015-06-25
Difluorolactam Compounds As Ep4 Receptor-selective Agonists For Use In The Treatment Of Ep4-mediated Diseases And Conditions App 20150175538 - Barrett; Stephen Douglas ; et al.	2015-06-25
Fluorescent Molecular Probes For Use In Assays That Measure Test Compound Competitive Binding With Sam-utilizing Proteins App 20120295283 - Barrett; Stephen Douglas ; et al.	2012-11-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.